Evidence suggests that the newly described estrogen receptor beta (ER-beta)
may be important for estrogen (17 beta -estradiol) action on the skeleton,
but its cellular localization in adult human bone requires clarification.
We addressed this by using indirect immunoperoxidase with a novel affinity
purified polyclonal antibody to human ER-beta, raised to hinge domain (D) s
equences from the human receptor. Bone was demineralized in 20% EDTA and al
l biopsy specimens were formalin-fixed and was-embedded. Vigorous retrieval
was essential for ER-beta detection. In sections (5 mum) of benign prostat
e hyperplasia, used as positive control, clear nuclear immunoreactivity was
seen in glandular epithelial cells, with a 1:500 dilution of ER-beta 40. F
or bone sections, optimal antibody dilutions were 1:100-1:250. We found tha
t in normal bone (from graft operations), in fracture callus front both men
and women (>25 years old), pagetic bone, osteophytes, and secondary hyperp
arathyroid bone, all from older patients, ER-beta was expressed clearly in
osteoclast nuclei, with little cytoplasmic immunoreactivity. Nuclear immuno
reactivity was stilt prominent in osteoclasts, with antibody diluted 1:500,
although it faded in other cells. Osteoblasts, in areas of active bone for
mation or bone remodeling, also expressed ER-beta, as did some osteocytes.
However, hypertrophic chondrocytes were negative, unlike mesenchymal cells,
adjacent to the osteogenesis. Megakaryocytes and some capillary blood vess
els cells were receptor positive. All ER-beta expression was blocked totall
y by preincubation of antibody with antigen. We conclude that ER-beta is ex
pressed in cells of osteoblast lineage and in osteoclasts. The latter appea
r relatively abundant in this receptor and this might provide a means for d
irect action of estrogen on osteoclasts.